Health Affairs, 26, no. 2 (2007): 483-491
doi: 10.1377/hlthaff.26.2.483
© 2007 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Figures Only
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (2)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Kesselheim, A. S.
* Articles by Mello, M. M.
* Search for Related Content
PubMed
* Articles by Kesselheim, A. S.
* Articles by Mello, M. M.
Related Collections
* Legal/Regulatory Issues
* Business Of Health
* Pharmaceuticals
* Research And Technology
* Consumer Issues

Health Tracking

MARKETWATCH

Confidentiality Laws And Secrecy In Medical Research: Improving Public Access To Data On Drug Safety

Aaron S. Kesselheim and Michelle M. Mello

Pharmaceutical manufacturers have long considered results collected from drugs’ clinical trials to be confidential information or trade secrets, even after submission to the Food and Drug Administration (FDA). We describe FDA policies regarding disclosure of clinical trial data and evaluate how courts have interpreted the Freedom of Information Act in cases seeking access to unreleased information. Recent examples of approved drugs later found to have dangerous side effects show the importance of complete dissemination of safety information. We suggest regulatory and legislative policy changes regarding how the FDA handles confidential information that can improve understanding of the risks of prescription drugs.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Review of Public Personnel AdministrationHome page
P. E. French and D. Goodman
The New Mental Health Parity Law: Issues and Concerns for Public and Private Sector Employers
Review of Public Personnel Administration, June 1, 2009; 29(2): 189 - 196.
[Abstract] [PDF]


Home page
NEJMHome page
A. J.J. Wood
Progress and Deficiencies in the Registration of Clinical Trials
N. Engl. J. Med., February 19, 2009; 360(8): 824 - 830.
[Full Text] [PDF]


Home page
NEJMHome page
A. S. Kesselheim and J. Avorn
Pharmaceutical Promotion to Physicians and First Amendment Rights
N. Engl. J. Med., April 17, 2008; 358(16): 1727 - 1732.
[Full Text] [PDF]


Home page
JAMAHome page
T. A. Brennan and M. M. Mello
Sunshine Laws and the Pharmaceutical Industry
JAMA, March 21, 2007; 297(11): 1255 - 1257.
[Full Text] [PDF]